enGene Inc. appoints Jason Hanson as new president and CEO

by • July 16, 2018 • Feature Slider, Feature-Home, Featured-Slides-Home, Management UpdatesComments Off on enGene Inc. appoints Jason Hanson as new president and CEO406

Jason Hanson, president, CEO, and director of enGene Inc.

Anthony Cheung Ph.D. steps down from being president and chief executive officer (CEO) of enGene Inc. His successor is Jason D. Hanson who will fill the shoes as president, CEO, and director of the biotechnology company focused on non-viral vector gene therapies.

“We are fortunate to have recruited someone with Jason’s experience and talent and I really look forward to working with Jason as enGene enters this exciting new stage of development,” says Dr. Cheung, now the chief technology officer of enGene.  “I am extremely proud that the promise of our innovative gene delivery platform and the milestones our team has accomplished to date have attracted an industry veteran of Jason’s caliber to lead enGene.”

Hanson most recently served as president and chief executive officer of Ohana Biosciences, a biotechnology company based in Cambridge, MA. He previously served as executive vice president and chief strategy officer for NuVasive, Inc. and as corporate vice president of General Electric Company and member of the senior executive team of GE Healthcare.

While at GE Healthcare he had global business responsibilities for a range of portfolio management, corporate development, legal, compliance, and government relations activities. Prior to joining GE Healthcare, Hanson served as company group chairman and executive vice president at Valeant Pharmaceuticals with responsibility for the company’s Consumer, Ophthalmology, Latin American and Dental businesses, as well as the manufacturing and supply chain, R&D, regulatory and medical affairs teams.

Hanson was the executive vice president and chief operating officer at Medicis Pharmaceutical Corporation, where he led R&D and other critical functions and helped build the renowned pipeline of prescription dermatology and aesthetic medicine products prior to its acquisition by Valeant for $2.6 billion.  He received a bachelor’s degree from Cornell University and a law degree from Duke University School of Law.

“I am thrilled to lead enGene into its new phase of growth,” says Hanson. “The company has made groundbreaking advancements to its gene delivery platform that will transform the way we treat many diseases.  Our vision is to make protein therapies universally available and curative for the improvement of patient’s lives.”

enGene Inc. is developing a proprietary gene therapy platform for localized delivery of proteins to mucosal cells lining the gut, and other tissues of the body, for the treatment of a range of diseases.

Comments are closed.